Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer.
Eph receptors constitute the largest family of receptor tyrosine kinases in the human genome. EphA2 is one prominent member that is overexpressed and functionally altered in many invasive cancers, including pancreatic cancer. Dasatinib, which is a multi-targeted kinase inhibitor mainly developed for Bcr-Abl and Src family kinases, has recently been shown to have significant activity against EphA2. As selective small molecule EphA2 inhibitors are not currently available, we investigated the therapeutic potential to target EphA2 by dasatinib in pancreatic cancer cell lines. Using in vitro kinase assays, we found that EphA2 receptor tyrosine kinase was inhibited directly by dasatinib in a dose-dependent manner. Stimulation with ephrinA1 produced rapid increases of EphA2 phosphorylation that were inhibited by dasatinib, although the effects on activation of downstream signalling differed among the pancreatic cancer cell lines. Dasatinib also inhibited ligand-induced binding of EphA2 to the ubiquitin ligase Cbl, and the internalisation and degradation of EphA2, suggesting that these processes are dependent on kinase activity. Treatment with dasatinib decreased EphA2 phosphorylation in BxPC-3 xenografts, suggesting that dasatinib might have activity in pancreatic cancer due to EphA2 inhibition, besides its effects on Src.
Chang
Q
Q
Division of Applied Molecular Oncology, Ontario Cancer Institute/Princess Margaret Hospital, Toronto, Ontario, Canada.
Jorgensen
C
C
Pawson
T
T
Hedley
D W
DW
D000818:Animals; D045744:Cell Line, Tumor; D000069439:Dasatinib; D006801:Humans; D008297:Male; D051379:Mice; D016513:Mice, SCID; D008856:Microscopy, Fluorescence; D010190:Pancreatic Neoplasms / Q000201:enzymology / Q000473:pathology*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D011743:Pyrimidines / Q000494:pharmacology*; D036104:Receptor, EphA2 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D015398:Signal Transduction; D013844:Thiazoles / Q000494:pharmacology*
D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D036104:Receptor, EphA2; D000069439:Dasatinib
Oncogene. 2002 Oct 31;21(50):7690-9
12400011
Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6924-32
16203784
J Neurosci. 2004 Jul 14;24(28):6248-57
15254079
Int J Cancer. 1995 Jan 3;60(1):129-36
7814145
Mol Cancer Ther. 2006 Dec;5(12):3014-22
17148760
Curr Biol. 2000 Jan 13;10(1):47-50
10660304
Cancer Res. 2006 Jul 15;66(14):7050-8
16849550
Oncogene. 2000 Nov 20;19(49):5614-9
11114742
Curr Cancer Drug Targets. 2005 May;5(3):149-57
15892616
Am J Pathol. 2006 Mar;168(3):962-72
16507911
Int J Cancer. 2003 Feb 20;103(5):657-63
12494475
Am J Pathol. 2003 Apr;162(4):1037-42
12651595
Clin Cancer Res. 2003 Feb;9(2):613-8
12576426
J Biol Chem. 2003 May 2;278(18):15789-93
12600984
Blood. 2007 Dec 1;110(12):4055-63
17720881
Nat Cell Biol. 2003 Oct;5(10):869-78
12973358
Cancer Res. 2007 Mar 15;67(6):2800-8
17363602
Clin Exp Metastasis. 2006;23(7-8):357-65
17146615
Nature. 1995 Oct 19;377(6550):591-4
7566171
Nat Cell Biol. 2001 May;3(5):527-30
11331884
Genome Biol. 2007;8(11):R255
18047674
Clin Cancer Res. 2001 Nov;7(11):3640-8
11705887
Oncogene. 2003 Jan 30;22(4):548-54
12555068
Cancer Cell. 2005 Aug;8(2):111-8
16098464
Biochem Biophys Res Commun. 2004 Aug 6;320(4):1096-102
15249202
Nat Rev Mol Cell Biol. 2002 Jul;3(7):475-86
12094214
Biochem Soc Trans. 1995 Aug;23(3):446-50
8566335
Nature. 2005 Jun 23;435(7045):1126-30
15973414
Microsc Res Tech. 2002 Oct 1;59(1):58-67
12242697
Neoplasia. 2006 Jan;8(1):18-30
16533422
Cancer Res. 2002 May 15;62(10):2840-7
12019162
J Biol Chem. 1994 Dec 2;269(48):30154-7
7982920
Oncogene. 2000 Dec 7;19(52):6043-52
11146556
Clin Cancer Res. 2007 Jul 15;13(14):4233-44
17634553
J Natl Cancer Inst. 2006 Nov 1;98(21):1558-70
17077358
Nat Cell Biol. 2000 Feb;2(2):62-9
10655584
Nat Biotechnol. 2007 Sep;25(9):1035-44
17721511
Oncogene. 2002 Oct 10;21(46):7011-26
12370823
Cancer Res. 2005 Aug 1;65(15):6910-8
16061675
EMBO J. 1997 Jul 1;16(13):3877-88
9233798
Cancer Res. 2007 Mar 1;67(5):2226-38
17332353
Nat Neurosci. 2004 May;7(5):417-8
15114347
Oncogene. 2005 Nov 24;24(53):7859-68
16103880
Cancer Res. 2001 Mar 1;61(5):2301-6
11280802
Cancer Res. 2004 Feb 1;64(3):910-9
14871820
Nat Rev Cancer. 2004 Jun;4(6):470-80
15170449
Exp Cell Res. 2001 Jul 1;267(1):81-7
11412040
Cell Growth Differ. 1999 Sep;10(9):629-38
10511313
Mol Cancer Res. 2002 Nov;1(1):79-87
12496371
N Engl J Med. 2006 Jun 15;354(24):2531-41
16775234
Nat Genet. 2004 Sep;36(9):979-83
15300251
Clin Exp Metastasis. 2003;20(1):59-68
12650608
J Med Chem. 2004 Dec 30;47(27):6658-61
15615512
Biochem Biophys Res Commun. 2002 Aug 9;296(1):214-20
12147253